Syngenta Biotechnology (Research Triangle Park) announced it has entered into a research and commercial license agreement with Chromatin for the Chicago-based company's coma proprietary gene stacking technology.
Chromatin has developed a novel approach to gene stacking, using the plant's own DNA to deliver several genes on a mini-chromosome. Under the agreement, Syngenta has obtained non-exclusive rights to use Chromatin's gene stacking technology for trait genes in corn and soybeans.
"Growers need increasingly more sophisticated tools to meet the demands on the agriculture market, and stacked traits along with improved seed germplasm will be instrumental," said Roger Kemble, head of Syngenta Crop Genetics Research. "We will evaluate this technology in combination with our own innovative research programs and strong pipeline as part of our intense commitment to speed delivery of products to market."
Further terms of the deal were not disclosed.